小檗堿合并利培酮對精神分裂癥患者血清BDNF、CRP及認知功能影響研究
發(fā)布時間：2018-09-06 06:29
【摘要】：目的:精神分裂癥是一種病因及發(fā)病機制未明的慢性重型精神疾病,除神經遞質假說外,還可能與神經營養(yǎng)及神經損傷有關,炎性反應也可能在精神類疾病發(fā)展中起重要作用,尤其與精神分裂癥的發(fā)生存在顯著的相關性。精神分裂癥進展過程中常常伴隨著認知功能受損,嚴重影響精神分裂癥患者的預后,成為公認的重大公共衛(wèi)生難題。研究表明,小檗堿具有拮抗氧化應激,抑制炎癥反應的作用。動物實驗表明,它還具有保護神經細胞,改善學習記憶功能等作用。然而這一作用僅限于動物研究水平,臨床研究未見報道。本課題探討小檗堿對精神分裂癥患者血清BDNF、CRP水平及認知功能的影響及其可能作用機制,為進一步探討精神分裂癥的發(fā)病機理,尋找新的治療方法提供線索。方法:本研究采用隨機雙盲、安慰劑對照的研究方法,根據DSM-V關于精神分裂癥的診斷標準選取精神分裂癥住院患者64名,所有入組的受試者均使用利培酮單藥治療。隨機將患者分為研究組與對照組,兩組性別、年齡均相匹配,且維持入組時利培酮治療劑量。研究組用藥為利培酮合并小檗堿(300 mg TID)治療,對照組用藥為利培酮合并小檗堿安慰劑治療,治療周期為12周。受試者在第0周入組時進行基線測驗,測量基線血清BDNF及CRP水平,進行認知功能測評,包括連線測驗(TMTA)、符號編碼測驗(SC)、流暢性、迷宮測驗、情緒智商測驗、PSP量表評分。在研究的第12周末,重復上述測定內容,比較治療前后上述指標的差異水平,評估小檗堿對精神分裂癥患者血清BDNF、CRP水平及認知功能的影響。數據結果分析采用SPSS17.0統(tǒng)計軟件包進行,P值小于0.05為差異具有顯著性。結果:1、與基線相比,研究組血清BDNF水平在第12周末的差異具有統(tǒng)計學意義(P0.01);治療后組間比較,研究組和對照組BDNF水平的差異均具有統(tǒng)計學意義(P0.05)。2、與基線相比,研究組CRP水平在第12周末的差異具有統(tǒng)計學意義(P0.01);治療后組間比較,研究組和對照組CRP水平的差異均具有統(tǒng)計學意義(P0.05)。3、治療12周末與基線相比,研究組在處理速度維度各項目、迷宮測驗、情緒智商測驗均有顯著改善(P0.01);治療后組間比較,研究組和對照組處理速度維度各項目粗分、情緒智商測驗差異均具有統(tǒng)計學意義(P0.05)。4、治療12周末與基線相比,研究組社會中有益的活動、個人關系和社會關系、自我照料、擾亂及攻擊行為、PSP總分的差異具有統(tǒng)計學意義(P0.05);治療后組間比較,研究組和對照組社會中有益的活動評分具有顯著差異(P0.05)。結論:1、小檗堿可升高利培酮單藥治療的精神分裂癥患者血清BDNF水平,具有神經保護作用。2、小檗堿可降低利培酮單藥治療的精神分裂癥患者CRP水平,抑制炎癥反應。3、小檗堿可顯著改善利培酮治療精神分裂癥患者認知功能,對信息處理速度、社會認知、工作學習能力有改善作用,而對患者的執(zhí)行功能并無改善作用。
[Abstract]:Objective: schizophrenia is a chronic severe mental disease with unknown etiology and pathogenesis. In addition to the neurotransmitter hypothesis, it may also be related to neurotrophic and nerve injury. Inflammatory reaction may also play an important role in the development of mental diseases. In particular, there is a significant correlation with the occurrence of schizophrenia. Cognitive impairment is often associated with the progression of schizophrenia, which seriously affects the prognosis of patients with schizophrenia and has become a recognized major public health problem. The results showed that berberine could antagonize oxidative stress and inhibit inflammatory reaction. Animal experiments show that it can also protect nerve cells and improve learning and memory function. However, this effect is limited to animal research level, clinical studies have not been reported. The purpose of this study was to investigate the effect of berberine on serum BDNF,CRP level and cognitive function and its possible mechanism in schizophrenic patients, and to provide clues for further exploring the pathogenesis of schizophrenia and finding new treatment methods. Methods: a randomized, double-blind, placebo-controlled study was conducted to select 64 schizophrenic inpatients according to DSM-V 's criteria for schizophrenia. All subjects were treated with risperidone alone. The patients were randomly divided into study group and control group. The study group was treated with risperidone combined with berberine (300 mg TID), the control group was treated with risperidone and berberine placebo for 12 weeks. At week 0, baseline test was performed, baseline serum BDNF and CRP levels were measured, and cognitive function was evaluated, including (SC), fluency, maze test and emotional intelligence quotient test (EIQ). At the end of the 12th week of the study, the above measurement was repeated to compare the difference of the above indexes before and after treatment, and to evaluate the effect of berberine on serum BDNF,CRP level and cognitive function in schizophrenic patients. Data analysis using SPSS17.0 statistical software package for P < 0. 05 had significant difference. Results compared with the baseline, the serum BDNF level of the study group was significantly different from that of the baseline (P0.01), and the difference between the study group and the control group was statistically significant after treatment (P0.05) .2Compared with the baseline. The difference of CRP level in the study group at the 12th weekend was statistically significant (P0.01); after treatment, the difference of CRP level between the study group and the control group was statistically significant (P0.05) .3.Compared with the baseline at the end of the 12th week, the study group was in each item of processing speed dimension. Labyrinth test and emotional IQ test were significantly improved (P0.01). After treatment, there were significant differences between the study group and the control group in the processing speed dimension of each item coarse score, emotional IQ test difference was statistically significant (P0.05) .4, 12 weeks after treatment compared with the baseline, There were statistically significant differences in the total scores of beneficial activities, personal relationships and social relations, self-care, disturbance and aggression in the study group (P0.05). There was significant difference in the score of beneficial activities between the study group and the control group (P0.05). Conclusion berberine can increase the level of serum BDNF in schizophrenic patients treated with risperidone, and has neuroprotective effect. Berberine can decrease the level of CRP in patients with schizophrenia treated with risperidone alone. Inhibition of inflammatory response. 3. Berberine can significantly improve the cognitive function of patients with schizophrenia treated with risperidone. It can improve the speed of information processing, social cognition and working and learning ability, but has no effect on the executive function of the patients.
【學位授予單位】：天津醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2016
【分類號】：R749.3
[Abstract]:Objective: schizophrenia is a chronic severe mental disease with unknown etiology and pathogenesis. In addition to the neurotransmitter hypothesis, it may also be related to neurotrophic and nerve injury. Inflammatory reaction may also play an important role in the development of mental diseases. In particular, there is a significant correlation with the occurrence of schizophrenia. Cognitive impairment is often associated with the progression of schizophrenia, which seriously affects the prognosis of patients with schizophrenia and has become a recognized major public health problem. The results showed that berberine could antagonize oxidative stress and inhibit inflammatory reaction. Animal experiments show that it can also protect nerve cells and improve learning and memory function. However, this effect is limited to animal research level, clinical studies have not been reported. The purpose of this study was to investigate the effect of berberine on serum BDNF,CRP level and cognitive function and its possible mechanism in schizophrenic patients, and to provide clues for further exploring the pathogenesis of schizophrenia and finding new treatment methods. Methods: a randomized, double-blind, placebo-controlled study was conducted to select 64 schizophrenic inpatients according to DSM-V 's criteria for schizophrenia. All subjects were treated with risperidone alone. The patients were randomly divided into study group and control group. The study group was treated with risperidone combined with berberine (300 mg TID), the control group was treated with risperidone and berberine placebo for 12 weeks. At week 0, baseline test was performed, baseline serum BDNF and CRP levels were measured, and cognitive function was evaluated, including (SC), fluency, maze test and emotional intelligence quotient test (EIQ). At the end of the 12th week of the study, the above measurement was repeated to compare the difference of the above indexes before and after treatment, and to evaluate the effect of berberine on serum BDNF,CRP level and cognitive function in schizophrenic patients. Data analysis using SPSS17.0 statistical software package for P < 0. 05 had significant difference. Results compared with the baseline, the serum BDNF level of the study group was significantly different from that of the baseline (P0.01), and the difference between the study group and the control group was statistically significant after treatment (P0.05) .2Compared with the baseline. The difference of CRP level in the study group at the 12th weekend was statistically significant (P0.01); after treatment, the difference of CRP level between the study group and the control group was statistically significant (P0.05) .3.Compared with the baseline at the end of the 12th week, the study group was in each item of processing speed dimension. Labyrinth test and emotional IQ test were significantly improved (P0.01). After treatment, there were significant differences between the study group and the control group in the processing speed dimension of each item coarse score, emotional IQ test difference was statistically significant (P0.05) .4, 12 weeks after treatment compared with the baseline, There were statistically significant differences in the total scores of beneficial activities, personal relationships and social relations, self-care, disturbance and aggression in the study group (P0.05). There was significant difference in the score of beneficial activities between the study group and the control group (P0.05). Conclusion berberine can increase the level of serum BDNF in schizophrenic patients treated with risperidone, and has neuroprotective effect. Berberine can decrease the level of CRP in patients with schizophrenia treated with risperidone alone. Inhibition of inflammatory response. 3. Berberine can significantly improve the cognitive function of patients with schizophrenia treated with risperidone. It can improve the speed of information processing, social cognition and working and learning ability, but has no effect on the executive function of the patients.
【學位授予單位】：天津醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2016
【分類號】：R749.3
【相似文獻】
相關期刊論文 前10條
1 周偉青;;急性冠狀動脈綜合征檢測CRP的臨床意義[J];現(xiàn)代醫(yī)藥衛(wèi)生;2006年21期
2 趙蕾;葉紅;何秉賢;;阻塞性睡眠呼吸暫停低通氣綜合征患者CRP的研究[J];中國醫(yī)刊;2007年04期
3 趙金強;高敏;成宇;;CRP在兒童急性呼吸道感染疾病中的應用[J];中國熱帶醫(yī)學;2008年09期
4 秦睿君;王萍;王虹;喬可宏;馬艷兵;尚曉鳳;鄭曙光;郭長城;尹慧婷;李虹;;阻塞性睡眠呼吸暫停低通氣綜合征患者血清瘦素和CRP水平的變化及相關性研究[J];中國當代醫(yī)藥;2011年23期
5 木尼蘭;周昕科;王建梅;趙宏偉;;CRP與兒童阻塞性睡眠呼吸暫停綜合征分析研究[J];新疆醫(yī)學;2011年08期
6 陳桂媛;;妊娠高血壓綜合征患者血清Hcy和CRP水平的初步觀察[J];臨床檢驗雜志;2011年09期
7 郭玉巖;王淑玲;林增秀;王海燕;蘭立強;寇寧;;2型糖尿病勃起功能障礙者內皮細胞舒張功能與CRP的相關研究[J];實用糖尿病雜志;2013年04期
8 應善清,宋怡 ,揚翰儀 ,孫榮武;分泌抗人CRP單克隆抗體雜交瘤細胞株的建立[J];白求恩醫(yī)科大學學報;1985年03期
9 劉建曉;李云霞;;白細胞參數及超敏CRP的檢測在妊娠期高血壓疾病中的應用[J];現(xiàn)代醫(yī)學;2014年04期
10 華一民;;CRP與糖尿病心血管并發(fā)癥的關系[J];中國誤診學雜志;2007年02期
相關會議論文 前10條
1 劉蘭波;范丹;;CRP在鑒別兒童血液系統(tǒng)惡性腫瘤初診發(fā)熱原因中的臨床意義[A];2012年江浙滬兒科學術年會暨浙江省醫(yī)學會兒科學分會學術年會、兒內科疾病診治新進展國家級學習班論文匯編[C];2012年
2 戴學軍;陸東紅;;小兒急性呼吸道感染時CRP的檢測及臨床意義[A];第三屆浙江中西部科技論壇論文集（第九卷 預防分卷）[C];2006年
3 張慧斐;王冬蓮;阮奕;何小帆;;D二聚體、CRP及脂聯(lián)素在慢性阻塞性肺疾病的臨床意義[A];2012年浙江省檢驗醫(yī)學學術年會論文集[C];2012年
4 陳墾;湯斌;梁堅;王婉梅;曹軍;;檢測自發(fā)性細菌性腹膜炎患者腹水中G-CSF和CRP的臨床意義(摘要)[A];第九次全國中西醫(yī)結合肝病學術會議論文集[C];2000年
5 呂圓圓;劉艷霞;孫慧君;;熊果酸抑制肝臟合成CRP及對CRP致血管內皮細胞損傷的保護作用[A];中國藥理學會第十次全國學術會議�？痆C];2009年
6 邵波;滕靈方;;自發(fā)性蛛網膜下腔出血后TNF-α、IL-6及CRP的動態(tài)變化及其臨床意義[A];2011年浙江省神經外科學學術年會論文匯編[C];2011年
7 陳浩;方邦江;張靜U，
本文編號：2225537
本文鏈接：http://sikaile.net/yixuelunwen/jsb/2225537.html
最近更新
教材專著
